scholarly journals Expression analisis of the ITSN2 and TKS5 mRNA isoforms in human malignant breast tumors

2018 ◽  
Vol 16 (1) ◽  
pp. 20-27
Author(s):  
S. V. Kropyvko ◽  
L. O. Tsyba ◽  
O. V. Novokhatska ◽  
L. A. Syvak ◽  
T. Ye. Tarasenko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Expression Analysis ◽  
Rna Isolation ◽  
Breast Tumors ◽  
Quantitative Real Time Pcr ◽  
Mrna Isoforms ◽  
Extensive Experience ◽  
Great Progress ◽  
Malignant Breast ◽  
The Many

Aim. Despite the great progress in cancer treating, the breast cancer remains lethal in 15 % cases. Regardless of the many years of research and extensive experience in the treatment of this type of cancer, one of the main problems in diagnosis and therapy is its high clinical and genetic heterogeneity. Thereby the identification of markers for personalized treatment of patients is still an actual issue. Methods. Collection of clinical material, RNA isolation, and expression analysis of ITSN2 and TKS5 isoforms using quantitative real time PCR with fluorescence-labeled probes. Results. We have found that ITSN2-S expression is reliably reduced in HER2/neu-positive tumors with poor prognosis. There were no significant differences in the expression of ITSN2-L and TKS5-L in the analyzed samples. Conclusions. These studies have demonstrated the possible use of ITSN2 short isoform (ITSN2-S) as a prognostic marker for breast cancer. Keywords: breast cancer, ITSN2, TKS5, expression analysis.

scholarly journals Primary breast lymphoma: a case report and review of the literature

2017 ◽  
Vol 7 (3) ◽  
Author(s):  
Kamal E.H. Mohamed ◽  
Rusha A.E. Ali
Keyword(s):  
Breast Cancer ◽  
Rare Case ◽  
Breast Tumors ◽  
Review Of The Literature ◽  
Primary Breast Lymphoma ◽  
Breast Lymphoma ◽  
First Case ◽  
High Prevalence ◽  
Malignant Breast ◽  
Hodgkin's Lymphomas

Primary breast lymphoma (PBL) represents 0.04-0.5% of all malignant breast tumors, <1% of all patients with non-Hodgkin’s lymphomas and 1.7-2.2% of all patients with extra nodal lymphomas. Despite the high prevalence of breast cancer, primary breast lymphoma is very rare. We report a rare case of PBL, successfully treated with surgery, chemotherapy and radiotherapy. This is the first case of PBL to be reported from Sudan to our knowledge.

Experience in performing organ-preserving and reconstructive plastic surgeries for malignant breast tumors at the Regional Clinical Center of Oncology in Khabarovsk

2021 ◽  
Vol 87 (1) ◽  
pp. 32-36
Author(s):  
A.A. Chernyayeva ◽  
◽  
A.S. Zenyukov ◽  
S.M. Korneyev ◽  
Ye.G. Lokalov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Local Recurrence ◽  
Clinical Oncology ◽  
Breast Tumors ◽  
Clinical Center ◽  
Malignant Breast ◽  
Oncology Center ◽  
Reconstructive Plastic

The article presents the experience of the Oncology department No. 1 of the Regional Clinical Oncology Center in Khabarovsk in performing organ-preserving and reconstructive plastic surgeries for breast cancer in the period 2014–2019. An assessment was made of the incidence of local recurrence or distant progression of the disease, as well as risk factors for their occurrence

scholarly journals Sex Steroid Hormones in Serum and Tissue of Benign and Malignant Breast Tumor Patients

2000 ◽  
Vol 16 (3-4) ◽  
pp. 151-157 ◽  
Author(s):  
Essam A. Mady ◽  
Ezz El-Din H. Ramadan ◽  
Alaa A. Ossman
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Steroid Hormones ◽  
Breast Tumor ◽  
Tumor Tissue ◽  
Breast Tumors ◽  
Sex Steroid ◽  
Malignant Breast Tumor ◽  
Malignant Breast ◽  
Benign Breast Tumors

The ability of breast tumors to synthesize sex steroid hormones is well recognized and their local production is thought to play a role in breast cancer development and growth. The aim of this study was to estimate local intra-tumoral and circulating levels of Estrone (E1), Estrone Sulfate (E1S), Estradiol (E2), Estriol (E3), and Testosterone (T) in 33 pre- and postmenopausal women with primary breast cancer in comparison to 12 pre- and postmenopausal women with benign breast tumors. The mean levels of the studied sex hormones were higher in serum and tumor tissue of breast cancer women than those with benign breast tumors apart from Testosterone which showed a significant decrease in pre- and postmenopausal women with breast cancer (P< 0.001 for follicular phase,P< 0.001 for luteal phase, andP< 0.001 for postmenopausal). The levels of the five hormones were significantly higher intra-tumoral than in serum of both benign and malignant breast tumor women with E1S as the predominant estrogen. There was only a positive significant correlation between serum and tumor tissue levels of E1(rs= 0.52,P< 0.05 for follicular;rs= 0.63,P< 0.05 for luteal andrs= 0.58,P< 0.05 for postmenopausal) and a significant correlation between serum and tumor tissue of T (rs= 0.64,P< 0.05 for follicular;rs= -0.51,P< 0.05 for luteal andrs= -0.81,P< 0.04 for postmenopausal).

scholarly journals Clinical value of peripheral blood M2/M1 like monocyte ratio in the diagnosis of breast cancer and the differentiation between benign and malignant breast tumors

2019 ◽  
Author(s):  
Mustafa Fadhil ◽  
Omar Abdul- Rasheed ◽  
Manwar Al-Naqqash
Keyword(s):  
Breast Cancer ◽  
Tumor Progression ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Tumor ◽  
Healthy Subjects ◽  
Breast Tumors ◽  
Breast Cancer Patients ◽  
Cancer Tumor ◽  
Malignant Breast

Background: During tumor progression, circulating monocytes and macrophages are actively recruited into tumors where they alter the tumor microenvironment to accelerate tumor progression. In response to multiple microenvironmental signals from the tumor and stromal cells, macrophages change their functional phenotypes. Based on their function, macrophages are commonly classified into both, classical M1 and alternative M2 macrophages. M2-like tumor-associated macrophages promote breast tumor growth and survival, and may migrate into the peripheral blood. However, the level of circulating M2/M1-like monocyte ratio in the peripheral blood of breast cancer patients has not been yet clarified. Aim: To compare peripheral blood M2/M1 monocyte ratio among breast cancer patients, benign breast tumor patients and healthy subjects. Also, to investigate the role of peripheral blood M2/M1 monocyte ratio as a circulating breast cancer tumor marker and to asses the validity of this marker in differentiation between benign and malignant breast tumors. Methods: Flow cytometry technique was used to determine the peripheral blood M2/M1 monocyte ratio in three groups of subjects, i.e. 45 patients with breast cancer, 40 patients with benign breast tumor, and 40 healthy subjects as a control group. The results of carbohydrate antigen15-3 (CA15-3) determination were analyzed comparatively. Results: The peripheral blood M2/M1 monocyte ratio in patients with breast cancer (0.27±0.1) was significantly higher (P<0.001) than that in healthy subjects (0.07±0.05) and than in benign tumor subjects (0.08±0.04). The area under the receiver operating characteristic (ROC) curve of peripheral blood M2/M1 monocyte ratio determination was significantly higher (P≤0.001) than that of CA15-3 levels. Conclusion: M2/M1-like monocyte ratio is of a high diagnostic value for breast cancer and is a promising differentiating marker between benign and breast cancer tumor groups.

scholarly journals Strategy of post-neoadjuvant treatment of patients with residual breast cancer

2020 ◽  
Vol 16 (1) ◽  
pp. 43-54
Author(s):  
V. V. Semiglazov ◽  
A. A. Natopkin
Keyword(s):  
Breast Cancer ◽  
Molecular Markers ◽  
Systemic Treatment ◽  
Neoadjuvant Treatment ◽  
Breast Tumors ◽  
Recurrence Risk ◽  
Molecular Profile ◽  
Malignant Breast ◽  
Selection Of ◽  
Biological Subtype

The article considers the aspects of selection of post-neoadjuvant therapy for patients with residual breast cancer depending on biological subtype and molecular profile of the tumor. Analysis of morphological and molecular markers allowing to evaluate sensitivity of malignant breast tumors with high recurrence risk to new types of systemic treatment is presented.

scholarly journals Pathohistological and Immunohistochemical Analysis, Differential Diagnosis, Prognosis and Complex Treatment in a Rare Lymphoepithelioma-Like Breast Cancer

2021 ◽  
Vol 4 (1) ◽  
Keyword(s):  
Breast Cancer ◽  
Differential Diagnosis ◽  
Clinical Case ◽  
Medical Literature ◽  
Immunohistochemical Analysis ◽  
Breast Tumors ◽  
Oncological Treatment ◽  
Malignant Breast ◽  
The Right ◽  
Epithelial Neoplasm

We present a 78-year-old woman with a rare neoplasm of the right mammary gland – Lymphoepithelioma-like carcinoma (LELC). Lymphoepithelioma-like carcinoma is an undifferentiated neoplasm, consisting of malignant epithelial cells on the background of lymphocytes. Pathomorphological features and immunohistochemical (IHC) analysis determines the rare pathohistological variant of breast cancer. This clinical case of lymphoepithelioma-like breast cancer is the 34th published in medical literature in English. In the discussion, we emphasize the importance of immunohistochemical analysis to assess the differential diagnosis with other benign and malignant breast tumors . Lymphoepithelioma-like breast cancer is an extremely malignant epithelial neoplasm with an unfavorable prognosis, requiring complex oncological treatment.

scholarly journals RELEVANCE OF DIAGNOSTICS AND TREATMENT OF BREAST CANCER IN MEN

2021 ◽  
pp. 3-7
Author(s):  
L. Alimkhodjaeva ◽  
M. Norbekova
Keyword(s):  
Breast Cancer ◽  
Genetic Testing ◽  
Adjuvant Chemotherapy ◽  
Prognostic Value ◽  
Molecular Subtypes ◽  
Breast Tumors ◽  
Malignant Breast ◽  
Molecular Assessment ◽  
Breast Cancer In Men

Breast cancer in men is a rare disease, accounting for approximately 0.1% of all malignant breast tumors in men and from 0.6% to 1% of all malignant breast tumors. The incidence of breast cancer in men increases with age for unknown reasons: the average age of men at the time of diagnosis is 67 years, compared with women, whose similar indicator is 57 years. Despite advances in the diagnostics and treatment of breast cancer in women, understanding and strategy for the treatment of breast cancer in men are limited and generally extrapolated from existing knowledge about breast cancer in women. In particular, the molecular subtypes of breast cancer in men have not been studied, although these subtypes have been associated with both biological and clinical features of breast cancer in women. It has been proven that molecular subtypes have an important prognostic value in breast cancer in women. Molecular assessment of tumors plays a significant role in the 22 prescriptions of adjuvant chemotherapy, and therefore the role of genetic testing increases.

Parallel Assessment of Circulatory Cell-Free DNA by PCR and Nucleosomes by ELISA in Breast Tumors

2008 ◽  
Vol 23 (2) ◽  
pp. 69-73 ◽  
Author(s):  
M. Seefeld ◽  
S. El Tarhouny ◽  
A.X.C. Fan ◽  
S. Hahn ◽  
W. Holzgreve ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quantitative Pcr ◽  
Breast Tumors ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Samples ◽  
Cell Free Dna ◽  
Free Dna ◽  
Significant Difference ◽  
Malignant Breast ◽  
Benign Breast Tumors

Objectives In order to assess the potential biomolecules for breast cancer, we analyzed in parallel the levels of cell-free glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and cell-free nucleosomes in serum samples from patients with benign and malignant breast tumors. The levels of cell-free DNA obtained by quantitative PCR were compared with those obtained by enzyme-linked immunosorbent assay (ELISA). Methods Twenty-three patients with benign breast tumors, 27 patients with breast cancer, and 32 age-matched healthy women were recruited. The amounts of serum nucleosomes were analyzed by ELISA and the levels of cell-free GAPDH were measured by real-time quantitative PCR. The correlation between nucleosome and cell-free GAPDH levels was examined using the Spearman rank test. Results The levels of cell-free GAPDH were significantly higher in the serum samples of patients with benign and malignant breast tumors than in those of the control group (median 37,966 GE/mL, range 3,802–130,104 versus 11,770 GE/mL, range 2,198–73,522, p=0.035 and median 40,698 GE/mL, range 3,644–192,482 versus 11,770 GE/mL range 2,198–73,522, p=0.001). The concentration of cell-free GAPDH correlated significantly with the quantities of nucleosomes in serum samples (r=0.451, p=0.000). There was, however, no significant difference between healthy individuals and women with benign breast tumors or breast cancer in terms of nucleosomes determined by ELISA. Conclusion Our data suggest that the cell-free serum GAPDH DNA assayed by quantitative PCR is a better biomarker than nucleosomes assayed by ELISA in patients with breast tumors.

Profile of anterior gradient 3 (AGR3) mRNA expression and serum levels in benign and malignant breast tumors

2021 ◽  
pp. 1-5
Author(s):  
Prihantono Prihantono ◽  
Warsinggih Rahardjo ◽  
Salman Ardi Syamsu ◽  
Nilam Smaradhania
Keyword(s):  
Breast Cancer ◽  
Mrna Expression ◽  
Serum Protein ◽  
Breast Tumors ◽  
Serum Levels ◽  
Protein Levels ◽  
Qrt Pcr ◽  
Potential Biomarker ◽  
Significant Difference ◽  
Malignant Breast

BACKGROUND: Benign and malignant breast tumors are the most commonly diagnosed tumor in females. Early and accurate diagnosis of malignancy is essential for effective breast cancer treatment. Human anterior gradient 3 (AGR3) has been suggested as a potential biomarker for the early detection and prognostic determination of breast cancer. OBJECTIVE: This study profiles AGR3 mRNA expression and serum protein levels in patients with benign and malignant breast tumors. METHODS: A case-control study was conducted on 40 benign and 40 malignant breast tumor patients in Makassar, Indonesia. AGR3 mRNA and protein were detected using qRT-PCR and ELISA, respectively. RESULTS: This study found significantly higher AGR3 mRNA expression in benign than malignant breast tumors using qRT-PCR (p < 0.001). In contrast, ELISA revealed no significant difference between AGR3 serum protein levels in benign and malignant breast tumors (p = 0.507). CONCLUSIONS: AGR3 is associated with non-aggressive tumors and could be used as a marker for less aggressive breast tumors.

Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.

1996 ◽  
Vol 14 (6) ◽  
pp. 1848-1857 ◽  
Author(s):  
N Avril ◽  
J Dose ◽  
F Jänicke ◽  
S Bense ◽  
S Ziegler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pet Imaging ◽  
Breast Imaging ◽  
Breast Tumors ◽  
Partial Volume Correction ◽  
Partial Volume ◽  
Volume Correction ◽  
Fdg Uptake ◽  
Significant Difference ◽  
Malignant Breast

PURPOSE To evaluate the diagnostic value of position emission tomographic (PET) imaging with F-18 fluorodeoxyglucose (FDG) in differentiating between benign and malignant breast tumors. PATIENTS AND METHODS Fifty-one patients, with suspicious breast lesions newly discovered either by physical examination or by mammography, underwent PET imaging before exploratory surgery. FDG-PET images of the breast were analyzed visually and quantitatively for objective assessment of regional tracer uptake. RESULTS Primary breast cancer was identified visually with a sensitivity of 68% to 94% and a specificity of 84% to 97% depending on criteria used for image interpretation. Quantitative analysis of FDG uptake in tumors using standardized uptake values (SUV) showed a significant difference between benign (1.4 +/- 0.5) and malignant (3.3 +/- 1.8) breast tumors (P < .01). Receiver operating characteristic (ROC) curve analysis exhibited a sensitivity of 75% and a specificity of 100% at a threshold SUV value of 2.5. Sensitivity increased to 92% with a corresponding specificity of 97% when partial volume correction of FDG uptake was performed based on independent anatomic information. CONCLUSION PET imaging allowed accurate differentiation between benign and malignant breast tumors providing a high specificity. Sensitivity for detection of small breast cancer ( < 1 cm) was limited due to partial volume effects. Quantitative image analysis combined with partial volume correction may be necessary to exploit fully the diagnostic accuracy. PET imaging may be helpful as a complimentary method in a subgroup of patients with indeterminate results of conventional breast imaging.

Sign in / Sign up

Export Citation Format

Share Document